Sei Investments Co. Purchases 102,485 Shares of AtriCure, Inc. $ATRC

Sei Investments Co. grew its position in AtriCure, Inc. (NASDAQ:ATRC) by 64.7% during the 1st quarter, Holdings Channel.com reports. The firm owned 260,788 shares of the medical device company’s stock after purchasing an additional 102,485 shares during the period. Sei Investments Co.’s holdings in AtriCure were worth $7,440,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Geneos Wealth Management Inc. bought a new position in shares of AtriCure during the second quarter worth approximately $37,000. Smartleaf Asset Management LLC boosted its stake in AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the period. Fifth Third Bancorp bought a new stake in AtriCure in the 1st quarter valued at $51,000. Global Retirement Partners LLC acquired a new position in AtriCure in the 4th quarter valued at $73,000. Finally, State of Wyoming acquired a new position in AtriCure in the 4th quarter valued at $75,000. Institutional investors own 99.11% of the company’s stock.

Key AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure’s recent second-quarter results exceeded expectations, with earnings per share of $0.18 versus the $0.13 analyst estimate and revenue of $153.6 million versus $151.8 million expected. The company also improved from a year-ago loss, supporting its growth and profitability outlook. AtriCure second-quarter results presentation
• Positive Sentiment: UBS lowered its price target from $55 to $50 but retained a Buy rating. The revised target still indicates meaningful potential upside and suggests the analyst remains constructive on AtriCure’s medical-device business. UBS AtriCure price target report
• Neutral Sentiment: Options-market coverage points to the possibility of a significant upcoming move in ATRC, but the available information does not establish whether traders are positioning for a rise or decline. Elevated options activity could contribute to short-term volatility. AtriCure options activity article
• Neutral Sentiment: New share-registration filings may give AtriCure additional financing flexibility. However, investors may monitor the filings for potential future share issuance and dilution. AtriCure share registration article
• Negative Sentiment: Insiders sold approximately $1.42 million of AtriCure shares. Director Sven Wehrwein reduced his position by about 38%, while insiders Justin J. Noznesky and Vinayak Doraiswamy each sold roughly 6% of their holdings. The clustered selling may weigh on sentiment, particularly after ATRC’s strong advance toward its 52-week high. AtriCure insider selling report

Analyst Upgrades and Downgrades

ATRC has been the subject of a number of research reports. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. UBS Group decreased their price target on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Finally, Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $48.50.

AtriCure Price Performance

AtriCure stock opened at $37.76 on Monday. The firm has a market cap of $1.92 billion, a PE ratio of 179.82 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The stock’s fifty day moving average price is $31.10 and its two-hundred day moving average price is $31.29. AtriCure, Inc. has a one year low of $25.36 and a one year high of $43.18.

AtriCure (NASDAQ:ATRC) last released its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The firm had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the prior year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts expect that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.

Insider Buying and Selling

In other AtriCure news, Director Karen Prange sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total value of $85,950.00. Following the transaction, the director directly owned 26,373 shares of the company’s stock, valued at $755,586.45. This trade represents a 10.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Vinayak Doraiswamy sold 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total transaction of $233,280.00. Following the completion of the transaction, the insider owned 86,511 shares of the company’s stock, valued at $3,363,547.68. The trade was a 6.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 40,182 shares of company stock worth $1,505,092 in the last ninety days. 4.00% of the stock is owned by company insiders.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.